Zobrazeno 1 - 10
of 267
pro vyhledávání: '"Adam J, Olszewski"'
Autor:
Natalie S. Grover, Kaitlin Annunzio, Marcus Watkins, Pallawi Torka, Reem Karmali, Andrea Anampa-Guzmán, Timothy S. Oh, Heather Reves, Montreh Tavakkoli, Emily Hansinger, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Nancy L. Bartlett, Geoffrey Shouse, Adam J. Olszewski, Narendranath Epperla
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract Marginal zone lymphoma (MZL) can have varied presentations and pathologic features, including high Ki-67 expression ( > 20%) as well as increased numbers of large B cells (LC). However, there are limited data available demonstrating the prog
Externí odkaz:
https://doaj.org/article/3bec38bae50949daa1b5c13aad65aef6
Autor:
Fatima N. Mirza, MD, MPH, Adam J. Olszewski, MD, Ari R. Pelcovits, MD, Christopher DiMarco, MD, Elnaz F. Firoz, MD
Publikováno v:
JAAD Case Reports, Vol 48, Iss , Pp 103-107 (2024)
Externí odkaz:
https://doaj.org/article/87449f1d90b3455d9992d8c03bdf0d3b
Autor:
Narendranath Epperla, Rina Li Welkie, Pallawi Torka, Geoffrey Shouse, Reem Karmali, Lauren Shea, Andrea Anampa-Guzmán, Timothy S. Oh, Heather Reaves, Montreh Tavakkoli, Kathryn Lindsey, Irl Brian Greenwell, Emily Hansinger, Colin Thomas, Sayan Mullick Chowdhury, Kaitlin Annunzio, Beth Christian, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Nancy L. Bartlett, Alex F. Herrera, Natalie S. Grover, Adam J. Olszewski
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-6 (2023)
Abstract Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior studies. However, many patients with MZL do not require immediate therapy, and the time from diagnosis
Externí odkaz:
https://doaj.org/article/4835afa60d3d4971aa7119bfb3356cb7
Autor:
Andrew Hsu, Kelsey E. Huntington, Andre De Souza, Lanlan Zhou, Adam J. Olszewski, Nirav P. Makwana, Diana O. Treaba, Ludimila Cavalcante, Francis J. Giles, Howard Safran, Wafik S. El-Deiry, Benedito A. Carneiro
Publikováno v:
Cancer Biology & Therapy, Vol 23, Iss 1, Pp 417-423 (2022)
GSK-3β is a serine/threonine kinase implicated in tumorigenesis and chemotherapy resistance. GSK-3β blockade downregulates the NF-κB pathway, modulates immune cell PD-1 and tumor cell PD-L1 expression, and increases CD8 + T cell and NK cell functi
Externí odkaz:
https://doaj.org/article/92cb5ee1490243b8bd245afdd67c0799
Autor:
Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara K. Moyo, Nishitha Reddy, Julia Sheets, David M. Weiner, Praveen Ramakrishnan Geethakumari, Malathi Kandarpa, Ximena Jordan Bruno, Colin Thomas, Michael C. Churnetski, Andrew Hsu, Luke Zurbriggen, Cherie Tan, Kathryn Lindsey, Joseph Maakaron, Paolo F. Caimi, Pallawi Torka, Celeste Bello, Sabarish Ayyappan, Reem Karmali, Seo-Hyun Kim, Anna Kress, Shalin Kothari, Yazeed Sawalha, Beth Christian, Kevin A. David, Irl Brian Greenwell, Murali Janakiram, Vaishalee P. Kenkre, Adam J. Olszewski, Jonathon B. Cohen, Neil Palmisiano, Elvira Umyarova, Ryan A. Wilcox, Farrukh T. Awan, Juan Pablo Alderuccio, Stefan K. Barta, Natalie S. Grover, Nilanjan Ghosh, Nancy L. Bartlett, Alex F. Herrera, Geoffrey Shouse
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-6 (2022)
Abstract Ibrutinib is effective in the treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL) with an overall response rate (ORR) of 48%. However, factors associated with response (or lack thereof) to ibrutinib in R/R MZL in clinical pra
Externí odkaz:
https://doaj.org/article/742e9377f2884da1b8eeb0b6ff560e57
Publikováno v:
Cancer Medicine, Vol 8, Iss 16, Pp 6945-6954 (2019)
Abstract Background Guidelines recommend bone‐modifying agents (BMAs) for all patients initiating treatment for myeloma. We examined adherence to this recommendation, and BMA effectiveness in the era of bortezomib/lenalidomide‐based therapy among
Externí odkaz:
https://doaj.org/article/eb0e03c08d55410cb0534af2db8bd51e
Autor:
Adam S. Zayac, Andrew M. Evens, Alexey Danilov, Stephen D. Smith, Deepa Jagadeesh, Lori A. Leslie, Catherine Wei, Seo-Hyun Kim, Seema Naik, Suchitra Sundaram, Nishitha Reddy, Umar Farooq, Vaishalee P. Kenkre, Narendranath Epperla, Kristie A. Blum, Nadia Khan, Daulath Singh, Juan P. Alderuccio, Amandeep Godara, Maryam Sarraf Yazdy, Catherine Diefenbach, Emma Rabinovich, Gaurav Varma, Reem Karmali, Yusra Shao, Asaad Trabolsi, Madelyn Burkart, Peter Martin, Sarah Stettner, Ayushi Chauhan, Yun Kyong Choi, Allandria Straker-Edwards, Andreas Klein, Michael C. Churnetski, Kirsten M. Boughan, Stephanie Berg, Bradley M. Haverkos, Victor M. Orellana-Noia, Christopher D'Angelo, David A. Bond, Seth M. Maliske, Ryan Vaca, Gabriella Magarelli, Amy Sperling, Max J. Gordon, Kevin A. David, Malvi Savani, Paolo Caimi, Manali Kamdar, Matthew A Lunning, Neil Palmisiano, Parameswaran Venugopal, Craig A. Portell, Veronika Bachanova, Tycel Phillips, Izidore S. Lossos, Adam J. Olszewski
Publikováno v:
Haematologica, Vol 106, Iss 7 (2021)
Central nervous system (CNS) involvement in Burkitt lymphoma (BL) poses a major therapeutic challenge, and the relative ability of contemporary regimens to treat CNS involvement remains uncertain. We described prognostic significance of CNS involveme
Externí odkaz:
https://doaj.org/article/7ae0d22933a943c387290b9e2d6a94f3
Publikováno v:
Case Reports in Infectious Diseases, Vol 2020 (2020)
Mixed invasive mold infections (MIMIs) are considered rare. We present a case of fatal aspergillosis and mucormycosis in an elderly host with history of chronic lymphocytic leukemia (CLL) and potential mold exposures. Notably, he had no classic risk
Externí odkaz:
https://doaj.org/article/95fb6efe03064c699184624ab62649c9
Autor:
Anna Chorzalska, Nagib Ahsan, R. Shyama Prasad Rao, Karim Roder, Xiaoqing Yu, John Morgan, Alexander Tepper, Steven Hines, Peng Zhang, Diana O. Treaba, Ting C. Zhao, Adam J. Olszewski, John L. Reagan, Olin Liang, Philip A. Gruppuso, Patrycja M. Dubielecka
Publikováno v:
Molecular Oncology, Vol 12, Iss 5, Pp 630-647 (2018)
The introduction of tyrosine kinase inhibitors (TKI) has transformed chronic myeloid leukemia (CML) into a chronic disease with long‐term survival exceeding 85%. However, resistance of CML stem cells to TKI may contribute to the 50% relapse rate ob
Externí odkaz:
https://doaj.org/article/61e7c5610dee4650acd0483ee9489b8a
Autor:
Rahul S. Bhansali, Fredrik Ellin, Miao Cao, Thomas Relander, Wenrui Li, Qi Long, Nivetha Ganesan, Robert Stuver, Steven M. Horwitz, Kitsada Wudhikarn, Steven R Hwang, N. Nora Bennani, Julio C. Chavez, Lubomir Sokol, Hayder Saeed, Frank Duan, Pierluigi Porcu, Priyanka Pullarkat, Neha Mehta-Shah, Jasmine Zain, Miguel Ruiz, Jonathan E Brammer, Rishab Prakash, Swami P. Iyer, Adam J. Olszewski, Ajay Major, Sonali M. Smith, Peter A. Riedell, Caroline Goldin, Bradley M. Haverkos, Bei Hu, Pamela B. Allen, Wael Toama, Murali Janakiram, Taylor Brooks, Deepa Jagadeesh, Nisha Hariharan, Aaron M Goodman, Paola Ghione, Fatima Fayyaz, Joanna M. Rhodes, Elise A. Chong, James N. Gerson, Daniel J. Landsburg, Sunita Dwivedy Nasta, Stephen J. Schuster, Jakub Svoboda, Mats Jerkeman, Stefan K. Barta
Publikováno v:
Blood. 140:1481-1484
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69b2196b50b3e2a198c4251230b77c07
https://doi.org/10.1182/blood-2022-160090
https://doi.org/10.1182/blood-2022-160090